
Meet The ‘Horned' American Bird Last Seen On Martha's Vineyard 92 Years Ago — Now Lost To The World Forever
Birds, more than other animal groups, have had a horrific time with extinction, especially over the ... More past several hundred years. Here's one uniquely American example.
The extinct heath hen (Tympanuchus cupido cupido) is historically interesting for a number of reasons, the first being that it is speculated to have been served at the Pilgrims' first thanksgiving.
This speculation makes some sense. Heath hens were abundant along the United States' northeastern shoreline in the 1600s. Odds are it would have been easier to round up a few heath hens to serve at dinner than wild turkeys, though turkeys wouldn't have been a big ask either.
In fact, heath hens came to be known as 'poor man's food' in the eighteenth century, as they were cheap and plentiful.
And, yet, by 1932, the species was gone. The story of the heath hen underscores an important ecological point: just because a species is plentiful doesn't mean it is impervious to extinction. Take the American passenger pigeon, for example – once among the most numerous birds on Earth, with flocks so vast they were said to darken the skies for hours in the 1800s. But by 1914, it too had vanished, wiped out by relentless hunting and widespread habitat loss.
(Sidebar: While humans have driven many bird species to extinction, the tables have occasionally turned. Meet four bird species known to attack humans – two with documented fatal consequences.)
Here's the unfortunate tale of the heath hen, and why it went extinct so quickly.
The heath hen, a subspecies of the greater prairie chicken, once thrived in the scrubby, coastal plains from Maine to Virginia. Its 'horns' – actually feathers on its head that males could raise during courtship displays – gave it a striking appearance.
In the spring, males would gather in leks and perform dramatic dances, puffing out orange air sacs on their necks and stomping their feet to show dominance and vitality. These 'booming grounds,' as they were often called, could be used for generations, sometimes over a century. In parts of their range, the spectacle became such a draw that it even attracted tourists.
A male greater prairie chicken in full spring display on the Midwestern prairie. The now-extinct ... More heath hen, once found along the eastern seaboard, performed similar courtship rituals on its own 'booming grounds' from New England to Virginia.
The heath hen was unique as the only member of the North American prairie chickens (genus Tympanuchus) found along the eastern seaboard. Its geographic isolation gave rise to a genetically distinct population that was smaller in size and redder in color than greater prairie chickens from the Midwest.
Sadly, the heath hen faced a rapid downfall. Overhunting was the first and most significant blow. By the early 1800s, the bird was already vanishing from much of its range. People hunted it with little restriction, often taking dozens in a day. Its reputation as cheap, easy protein made it a popular choice for colonists and later urban markets.
Hunting wasn't the only threat. As the northeastern United States industrialized, the bird's scrubby, fire-maintained habitat was replaced with farms, towns and roads. Fire suppression policies also allowed forests to grow denser, making them less suitable for the heath hen, and increasing the risk of devastating fires.
By the 1870s, the bird's range had contracted entirely to Martha's Vineyard, Massachusetts. There, a small, isolated population struggled on for decades. Conservationists attempted to save it, even establishing a reserve, but it was too little, too late. Disease, harsh winters, fires, inbreeding, and predators all took their toll.
The final blow came quietly. By 1929, only one known heath hen remained: a lonely male named 'Booming Ben.' He continued his courtship displays in vain for three years, calling for a mate who would never arrive. After 1932, he was never seen again.
Today, the heath hen serves as a poignant reminder: even a species that seems secure can vanish within the span of a human lifetime.
But if there's a silver lining, it's that the effort to save the heath hen marked one of the earliest coordinated attempts to prevent the extinction of an American bird. Although it came too late, the lessons it offered helped lay the foundation for future conservation successes – like the recovery of the whooping crane, trumpeter swan and wood duck. In this way, the loss of the heath hen helped shape a more hopeful path for the species that followed.
Does thinking about the extinction of a species instantly change your mood? Take the Connectedness to Nature Scale to see where you stand on this unique personality dimension.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
an hour ago
- Associated Press
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, 'Ascletis') announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) ( NCT06427590 ) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity ( NCT06972992 ) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact: Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) [email protected] Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) [email protected] [email protected] View original content: SOURCE Ascletis Pharma Inc.


CNN
2 hours ago
- CNN
New tech reveals never-before-seen details in solar corona
A breakthrough in adaptive optics technology captured the clearest images to date of the sun's corona. The incredible resolution of the new images could provide new insights on some of the mysteries surrounding our star.
Yahoo
3 hours ago
- Yahoo
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity (NCT06972992) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact: Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data